GU
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Developmental Therapeutics Highlights
FEATURING
Guru Sonpavde
- 251 views
- October 25, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Changing Trials for Patients With Localized MIBC - NIAGARA and AMBASSADOR
FEATURING
Petros Grivas
- 245 views
- September 20, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - EV-103 5-Year Follow-Up (la/mUC), NIAGARA (MIBC), and Other Updates
FEATURING
Elizabeth R. Plimack
- 173 views
- September 27, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Treatment
FEATURING
Guru Sonpavde
- 154 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: GU Practice-Changing Trial Results of PEACE-3 (mCRPC) and NIAGARA (MIBC)
FEATURING
Robert Dreicer
- 276 views
- September 24, 2024
- 2
ecancer
ESMO 2024: Optimizing the Personalization of Prostate Cancer Treatment
- 43 views
- October 22, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Practice-Shaping Prostate Cancer Trials
FEATURING
Eleni Efstathiou
- 83 views
- October 15, 2024
ecancer
ESMO 2024 Summary: Understanding the Use of PARPi Combinations to Treat Patients With mCRPC
- 23 views
- October 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder and RCC Highlights
FEATURING
Karine Tawagi,
Natalie Reizine
- 108 views
- October 10, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Bladder Cancer Highlights - JCOG1019, TOMBOLA, and SunRISe-4
FEATURING
Bogdana Schmidt
- 115 views
- September 23, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: The Latest Data on NMIBC and Localized MIBC
FEATURING
Félix Guerrero-Ramos
- 54 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Important GU Trials - ETER100 (RCC), TACITO (mRCC), and CheckMate 9ER (aRCC)
FEATURING
Camillo Porta
- 174 views
- October 2, 2024
- 3
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights of Radioligand Therapies in Prostate Cancer
FEATURING
Natalie Reizine,
Karine Tawagi
- 75 views
- October 10, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Novel Agents and Promising Combinations in mRCC and mUC
FEATURING
Begoña Pérez-Valderrama
- 59 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Managing Durable Responses and De-Escalation Strategies in Urothelial Cancer With Systemic Therapy
FEATURING
Debbie Robbrecht
- 23 views
- October 8, 2024
ecancer
ESMO 2024 Insights: PEACE-3 Trial - Enzalutamide Treatment Boosted by Radium-223 in mCRPC
FEATURING
Silke Gillessen
- 56 views
- October 11, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SWOG-1216 Trial - Inherited Variants in SRD5A Genes & Response to Hormonal Therapy in Prostate Cancer
FEATURING
Jacek Pinski
- 31 views
- October 11, 2024
ecancer
ESMO 2024 Insights: SUNNIFORECAST Trial - Nivo + Ipi vs. Standard of Care in Non-Clear-Cell RCCs
FEATURING
Lothar Bergmann
- 10 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Baseline Radiological Tumor Burden and Outcomes in mccRCC Treated With 1L IO-Based Regimens
FEATURING
Rashad Nawfal
- 13 views
- October 17, 2024
ecancer
ESMO 2024 Insights: JCOG1019 Study - Watchful Waiting vs. Intravesical BCG in HGT1 Bladder Cancer
FEATURING
Hiroshi Kitamura
- 26 views
- October 16, 2024
- 1
ecancer
ESMO 2024 Insights: Best Practice in HRRm Testing in Patients With Metastatic Prostate Cancer
- 92 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Circulating Tumor Cell Enumeration and OS in mCRPC Treated With Xaluritamig
FEATURING
Andrew Armstrong
- 30 views
- October 14, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Glycoproteomic Biomarkers as Predictors of NIVO+CABO vs. Sunitinib Response in aRCC - CheckMate 9ER
FEATURING
David Braun
- 82 views
- October 17, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Safety & Activity of First-in-Class Dual AR Degrader & Antagonist BMS-986365 in Heavily Pretreated mCRPC Patients
FEATURING
Andrew Armstrong
- 24 views
- October 16, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: 1L EV + Pembro in Cis-Ineligible la/mUC - 5-Year Follow-Up of Study EV-103 DE/A
FEATURING
Jonathan Rosenberg
- 44 views
- October 10, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: JCOG1019 Phase 3 Study Comparing the Effectiveness of Watchful Waiting & Intravesical BCG in Pts With HGT1 Bladder Cancer With pT0 on the 2nd Transurethral Resection Specimen
FEATURING
Hiroshi Kitamura
- 3 views
- October 10, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Futibatinib + Pembro in Advanced/Metastatic Urothelial Carcinoma - Final Analysis of Efficacy and Safety
FEATURING
Vadim Koshkin
- 59 views
- October 8, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Response Evaluation Using ctDNA and PET Imaging in mCRPC Treated With LuPSMA + Pembro - PRINCE Trial
FEATURING
Sofie Tolmeijer
- 110 views
- October 4, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Final Analysis of the Phase 3 LITESPARK-005 Study of Belzutifan vs. Everolimus in Patients With Previously Treated Advanced ccRCC
FEATURING
Brian Rini
- 94 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: STAMPEDE2 Comparison P - Upfront Accelerated 177Lu-PSMA-617 in mHSPC
FEATURING
Minal Padden-Modi,
Nick James
- 66 views
- September 25, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: TACITO Trial - Fecal Microbiota Transplantation vs. Placebo in Patients Receiving Pembro + Axitinib for mRCC
FEATURING
Chiara Ciccarese
- 154 views
- September 24, 2024
- 2
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: ORACLE Study - Outcomes With Novel Combination Therapies in Non-Clear Cell RCC
FEATURING
Deepak Kilari
- 15 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: INSPIRE Trial - Nivolumab and Ipilimumab in Molecularly Selected mCRPC Patients
FEATURING
Niven Mehra
- 118 views
- October 1, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SG + EV as ≥ 2L Therapy for mUC - Updated Efficacy Profile of the Double Antibody Drug Conjugate Trial
FEATURING
Bradley McGregor
- 63 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Multi-Gene Copy Number Variation Risk-Score for Predicting Survival and Therapy Response in Treatment-Naïve mCRPC
FEATURING
Manish Kohli
- 17 views
- October 1, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: EMBARK Study Post-Hoc Analysis By Age - Enzalutamide +/- Leuprolide in Patients With High-Risk Biochemically Recurrent Prostate Cancer
FEATURING
Neal Shore
- 58 views
- September 27, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: RAPSON Study - Radium223-Docetaxel vs. Docetaxel-Radium223 Sequence in mCRPC with Prospective Biomarker Evaluation
FEATURING
Vincenza Conteduca
- 22 views
- September 25, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: STAMPEDE2 Trial - Stereotactic Ablative Body Radiotherapy for Newly Diagnosed Oligometastatic Prostate Cancer Starting ADT
FEATURING
Hoda Abdel-Aty
- 101 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: PEACE-1 Trial - Phenotypic and Genomic Characterization of De Novo Metastatic Prostate Cancer
FEATURING
Cedric Pobel
- 27 views
- September 24, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: VOLGA Trial - ctDNA Clearance in Cisplatin-Ineligible MIBC With Durvalumab + Tremelimumab + Enfortumab Vedotin
FEATURING
Alexandra Drakaki
- 51 views
- September 23, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SOGUG-AUREA Study - Split-Dose Cisplatin and Atezolizumab in Cisplatin-Ineligible Urothelial Carcinoma
FEATURING
Guillermo de Velasco
- 56 views
- September 23, 2024
- 1
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Predictive Tumor Suppressor Gene Signature for Early Progression in mHSPC
FEATURING
Marta Garcia De Herreros
- 24 views
- September 20, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: SC vs. IV Nivolumab in Advanced/Metastatic RCC - Ph3 CheckMate 67T
FEATURING
Laurence Albiges
- 114 views
- September 19, 2024
- 1